Immunotherapy cocktail takes on deadly thyroid cancer
NCT ID NCT03181100
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 15 times
Summary
This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable disease will receive different drug combinations based on their cancer's genetics. The goal is to see if this approach controls the cancer better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.